Collaborative drug discovery and the Tres Cantos Antimalarial Set (TCAMS)

•Analyze the impact of the Tres Cantos AntiMalarial Set on the academic community.•Demonstrate added value in releasing large sets of information.•Show that productivity is inferior to company-fostered initiatives.•Provide examples for target identification, SAR exploration, and repurposing. Malaria...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2019-06, Vol.24 (6), p.1304-1310
Main Author: Cabrera, Alvaro Cortes
Format: Article
Language:English
Subjects:
Animals
Antimalarials - pharmacology
Antimalarials - therapeutic use
Drug Discovery - methods
Drug Evaluation, Preclinical - methods
Drug Resistance - drug effects
Humans
Malaria - drug therapy
Malaria - parasitology
Plasmodium falciparum - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Analyze the impact of the Tres Cantos AntiMalarial Set on the academic community.•Demonstrate added value in releasing large sets of information.•Show that productivity is inferior to company-fostered initiatives.•Provide examples for target identification, SAR exploration, and repurposing. Malaria affects a population of over 200 million people worldwide. New drugs are needed because of widespread resistance, and the hunt for such drugs involves a coordinated research effort from the scientific community. The release of the Tres Cantos Antimalarial Set (TCAMS) in 2010 represented a landmark in the field of collaborative drug discovery for malaria. This set of >13 000 molecules with confirmed activity against several strains of Plasmodium falciparum was publicly released with the goal of fostering additional research beyond the GlaxoSmithKline (GSK) network of collaborators. Here, we examine the outcomes realized from TCAMS over the past 8 years and whether the expectations surrounding this initiative have become a reality.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2019.04.005